PL EN


Preferences help
enabled [disable] Abstract
Number of results
2018 | 16 | 1 | 46–49
Article title

Metformina w leczeniu onkologicznym

Content
Title variants
EN
Metformin in cancer treatment
Languages of publication
PL EN
Abstracts
EN
Diabetes and obesity are associated with an augmented manifestation of malignant tumors of various localizations. Metformin is commonly used in patients with diabetes type 2, particularly those classed as obese. It has been shown to reduce both incidence of malignant tumors and respective mortality. The action of metformin involves a pleiotropic mechanism: it activates the LKB1/AMP pathway (liver kinase B1/adenosine monophosphate) which inhibits the mTOR pathway and blocks cell division also by its effect on cyclins. Additionally, metformin promotes apoptosis and cellular autophagy, inhibits the activity of metalloproteinases and activates the immune system. Metformin reduces the incidence of lung, pancreas, liver and large intestine cancers. It also reduces the percentage of triple-negative breast cancers and improves response to neoadjuvant chemotherapy in this disease. In endometrial cancer, metformin increases the positive influence of gestagens, potentiates the effects of paclitaxel and improves survival. In cervical cancer, metformin extends time to relapse, and in ovarian cancer, it extends time to progression and improves overall survival. Studies indicate that a destructive effect on cancer stem cells may be its additional mechanism of action.
PL
Cukrzyca i otyłość są związane ze zwiększonym występowaniem nowotworów złośliwych w różnych lokalizacjach. Metformina jest powszechnie stosowana u chorych z cukrzycą typu 2, zwłaszcza u osób otyłych. Wykazano, że obniża ona zarówno zachorowalność na nowotwory złośliwe, jak i umieralność z ich powodu. Mechanizm działania metforminy jest plejotropowy: aktywuje szlak LKB1/AMP (kinaza wątrobowa B1/adenozynomonofosforan), prowadząc do hamowania szlaku mTOR, hamuje podziały komórkowe również poprzez wpływ na cykliny, promuje apoptozę i autofagię komórek, hamuje aktywność metaloproteinaz i aktywuje układ immunologiczny. Metformina obniża zachorowalność na raka płuca, trzustki, wątroby i jelita grubego. Zmniejsza odsetek trójnegatywnych raków piersi oraz poprawia odpowiedź na neoadiuwantową chemioterapię w przypadku tego nowotworu. W raku endometrium potęguje działanie gestagenów, potencjalizuje wpływ paklitakselu i poprawia odsetek przeżyć. W przypadku raka szyjki macicy wydłuża czas do wznowy, a przy raku jajnika wydłuża czas do progresji oraz poprawia całkowity czas przeżycia. Badania wskazują, że jednym z dodatkowych mechanizmów działania metforminy może być jej destrukcyjny wpływ na komórki macierzyste raka.
Discipline
Publisher

Year
Volume
16
Issue
1
Pages
46–49
Physical description
Contributors
  • Klinika Perinatologii i Chorób Kobiecych, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Poznań, Polska. Kierownik: prof. dr hab. n. med. Krzysztof Drews
  • Oddział Chorób Wewnętrznych i Diabetologii, Szpital Kliniczny im. Heliodora Święcickiego Uniwersytetu Medycznego w Poznaniu, Poznań, Polska. Kierownik: lek. med. Patrycja Butrymowicz
References
  • 1. Garg SK, Maurer H, Reed K et al.: Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab 2014; 16: 97–110.
  • 2. Nagle CM, Crosbie EJ, Brand A et al.; Australian National Endometrial Cancer Study Group: The association between diabetes, comorbidities, body mass index and all-cause and causespecific mortality among women with endometrial cancer. Gynecol Oncol 2018; 150: 99–105.
  • 3. Bae WJ, Choi JB, Moon HW et al.: Influence of diabetes on the risk of urothelial cancer according to body mass index: a 10-year nationwide population-based observational study. J Cancer 2018; 9: 488–493.
  • 4. Minamii T, Nogami M, Ogawa W: Mechanisms of metformin action: in and out of the gut. J Diabetes Investig 2018; 9: 701–703.
  • 5. Shaw RJ, Lamia KA, Vasquez D et al.: The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310: 1642–1646.
  • 6. Dowling RJ, Zakikhani M, Fantus IG et al.: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67: 10804–10812.
  • 7. Kalender A, Selvaraj A, Kim SY et al.: Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 2010; 11: 390–401.
  • 8. Liang J, Shao SH, Xu ZX et al.: The energy sensing LKB1- AMPK pathway regulates p27kip1 phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007; 9: 218–224.
  • 9. Hirsch HA, Iliopoulos D, Tsichlis PN et al.: Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009; 69: 7507–7511.
  • 10. Del Barco S, Vazquez-Martin A, Cufí S et al.: Metformin: multifaceted protection against cancer. Oncotarget 2011; 2: 896–917.
  • 11. Evans JM, Donnelly LA, Emslie-Smith AM et al.: Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304–1305.
  • 12. Noto H, Goto A, Tsujimoto T et al.: Cancer risk in diabetic patients treated with metformin: a systematic review and metaanalysis. PLoS One 2012; 7: e33411.
  • 13. Lee MS, Hsu CC, Wahlqvist ML et al.: Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011; 11: 20.
  • 14. Sadeghi N, Abbruzzese JL, Yeung SC et al.: Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 2012; 18: 2905–2912.
  • 15. Garrett CR, Hassabo HM, Bhadkamkar NA et al.: Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer 2012; 106: 1374–1378.
  • 16. Berstein LM, Boyarkina MP, Tsyrlina EV et al.: More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin. Med Oncol 2011; 28: 1260–1263.
  • 17. Jiralerspong S, Palla SL, Giordano SH et al.: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27: 3297–3302.
  • 18. Xie Y, Wang YL, Yu L et al.: Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol 2011; 126: 113–120.
  • 19. Hanna RK, Zhou C, Malloy KM et al.: Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol Oncol 2012; 125: 458–469.
  • 20. Tang YL, Zhu LY, Li Y et al.: Metformin use is associated with reduced incidence and improved survival of endometrial cancer: a meta-analysis. Biomed Res Int 2017; 2017: 5905384.
  • 21. Hanprasertpong J, Jiamset I, Geater A et al.: The effect of metformin on oncological outcomes in patients with cervical cancer with type 2 diabetes mellitus. Int J Gynecol Cancer 2017; 27: 131–137.
  • 22. Han K, Pintilie M, Lipscombe LL et al.: Association between metformin use and mortality after cervical cancer in older women with diabetes. Cancer Epidemiol Biomarkers Prev 2016; 25: 507–512.
  • 23. Dilokthornsakul P, Chaiyakunapruk N, Termrungruanglert W et al.: The effects of metformin on ovarian cancer: a systematic review. Int J Gynecol Cancer 2013; 23: 1544–1551.
  • 24. Kumar S, Meuter A, Thapa P et al.: Metformin intake is associated with better survival in ovarian cancer: a case-control study. Cancer 2013; 119: 555–562.
  • 25. Zhang R, Zhang P, Wang H et al.: Inhibitory effects of metformin at low concentration on epithelial–mesenchymal transition of CD44+CD117+ ovarian cancer stem cells. Stem Cell Res Ther 2015; 6: 262.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-6f839f13-c87a-45a7-bcd1-8c4ca4dd9d0b
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.